MEDSCI (02415) announced that the group expects to record profit attributable to shareholders of not less than RMB 10 million for the six months ended June 30, 2025, compared to profit attributable to shareholders of RMB 0.2 million for the six months ended June 30, 2024.

The group expects the profit increase to be mainly attributable to the following factors: (i) recovery in the pharmaceutical industry and accelerated transformation of domestic pharmaceutical companies toward evidence-driven marketing models, driving increased demand for precision omnichannel marketing solutions; (ii) artificial intelligence applications empowering and enhancing operational efficiency across the group's business segments; and (iii) proactive implementation of environmental, social and governance principles, thereby achieving more effective control of operating costs.